Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RO7300490 in Advanced Solid Tumors
NCT04857138Phase 1Completed
- Sponsor
- Roche
- Start
- May 2021
- Primary completion
- Jan 2024
- Modality
- Bispecific Antibodies, Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 5
01
Overview
Phase 1, open-label trial of RO7300490 in solid tumor (3 arms), sponsored by Roche. Primary endpoints: Percentage of Participants with Adverse Events up to 36 months, Percentage of Participants with Dose-Limiting Toxicities up to 36 months and 1 more. Started May 2021; status: completed.
02
Drugs
RO7300490
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT04857138.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04857138.